GRF(1-29) raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-04-12 and is reviewed periodically as new material appears.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilized white powder | Supplied as a freeze-dried solid for research use |
| Molecular weight | Approximately 3,647 Da (DAC form) | Lower for the variant lacking the albumin-binding moiety |
| Solubility | Soluble in water and aqueous buffer | Typically dissolved in sterile or bacteriostatic water |
| Typical storage temperature | −20 °C or below | Dry powder, desiccated and protected from light |
| Common analytical method | Reversed-phase HPLC with mass spectrometry | Used for purity estimation and identity confirmation |
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
=== Visual and other effects of hormonal changes === Testosterone will cause an enlargement of the clitoris and possibly has important effects on the growth and maturation of the vestibular bulbs, corpora cavernosa of the clitoris and urethral sponge. Changes of the vulva initiated by estradiol as well as its direct effects also appear to influence the functioning of the lower urinary tract.
=== Stadtholderate under the House of Nassau-Dietz === When William III died childless, the patrilineal ancestry of Orange-Nassau became extinct. In contrast to other provinces of the Dutch Republic, Friesland, Groningen and Drenthe had mostly drawn their stadtholders from the House of Nassau-Dietz, that starting with John VI, the brother of William of Orange, and comprises in addition a cognatic line to William the Silent through his granddaughter Albertine Agnes of Nassau, who had married in 1652 into this Frisian cousin line.
== Interfacial potential == An interface is defined as the common boundary formed between two different phases, such as between a solid and gas. Electric potential, or charge, is the result of an object's capacity to be moved in an electric field. An interfacial potential is thus defined as a charge located at the common boundary between two phases (for example, an amino acid such as glutamate on the surface of a protein can have its side chain carboxylic acid deprotonated in environments with pH greater than 4.1 to produce a charged amino acid at the surface, which would create an interfacial potential). Interfacial potential is responsible for the formation of the electric double layer, which has a broad range of applications in what is termed electrokinetic phenomena. The development of the theory of the electric double layer is described below.
==== Potential complications ==== Several inpatient and outpatient procedures use sedation. Many drugs and agents used during surgery to relieve pain and to depress consciousness remain in the body at low amounts for hours or even days afterwards. In an individual with either central, obstructive or mixed sleep apnea, these low doses may be enough to cause life-threatening irregularities in breathing or collapses in a patient's airways. Use of analgesics and sedatives in these patients postoperatively should therefore be minimized or avoided. Surgery on the mouth and throat, as well as dental surgery and procedures, can result in postoperative swelling of the lining of the mouth and other areas that affect the airway. Even when the surgical procedure is designed to improve the airway, such as tonsillectomy and adenoidectomy or tongue reduction, swelling may negate some of the effects in the immediate postoperative period. Once the swelling resolves and the palate becomes tightened by postoperative scarring, however, the full benefit of the surgery may be noticed. A person with sleep apnea undergoing any medical treatment must make sure their doctor and anesthetist are informed about the sleep apnea. Alternative and emergency procedures may be necessary to maintain the airway of sleep apnea patients.
Sources: en.wikipedia.org
Michel Eugène Chevreul (French pronunciation: [miʃɛl øʒɛn ʃəvʁœl]; 31 August 1786 – 9 April 1889) was a French chemist whose work contributed to significant developments in science, medicine, and art. Chevreul's early work with animal fats revolutionized soap and candle manufacturing and led to his isolation of the heptadecanoic (margaric), stearic, and oleic fatty acids. In the process, Chevreul became the first scientist to define the concept of a chemical compound and the first to formally characterize the nature of organic compounds; he is consequently considered a founder of modern organic chemistry. In the medical field, Chevreul was first to demonstrate that diabetics excrete glucose in the urine and to isolate creatine. Chevreul's study of textile dyes while director of the Gobelins Manufactory in Paris led to color theories that "provided the scientific basis for Impressionist and Neo-Impressionist painting." Chevreul is one of the 72 French scientists, mathematicians, and engineers whose names are inscribed on the Eiffel Tower. He lived to be 102 and was a pioneer in the field of gerontology.
The BSE SENSEX (also known as the S&P Bombay Stock Exchange Sensitive Index or simply SENSEX) is an Indian free-float market-weighted stock market index of 30 well-established and financially sound companies listed on the Bombay Stock Exchange. The 30 constituent companies which are some of the largest and most actively traded stocks, are representative of various industrial sectors of the Indian economy. Published since 1 January 1986, the S&P BSE SENSEX is regarded as the pulse of the domestic stock markets in India. The base value of the SENSEX was taken as 100 on 1 April 1979 and its base year as 1978–79. On 25 July 2001, BSE launched DOLLEX-, a dollar-linked version of the SENSEX.
=== Fertilizer === Amino acids synthesized by living organisms such as methionine and cysteine contain organosulfur groups (thioester and thiol respectively). The antioxidant glutathione protecting many living organisms against free radicals and oxidative stress also contains organic sulfur. Some crops such as onion and garlic also produce different organosulfur compounds such as syn-propanethial-S-oxide responsible of lacrymal irritation (onions), or diallyl disulfide and allicin (garlic). Sulfates, commonly found in soils and groundwaters are often a sufficient natural source of sulfur for plants and bacteria. Atmospheric deposition of sulfur dioxide (SO2) is also a common artificial source (coal combustion) of sulfur for the soils. Under normal circumstances, in most agricultural soils, sulfur is not a limiting nutrient for plants and microorganisms (see Liebig's barrel). However, in some circumstances, soils can be depleted in sulfate, e.g. if this later is leached by meteoric water (rain) or if the requirements in sulfur for some types of crops are high. This explains that sulfur is increasingly recognized and used as a component of fertilizers. The most important form of sulfur for fertilizer is calcium sulfate, commonly found in nature as the mineral gypsum (CaSO4·2H2O). Elemental sulfur is hydrophobic (not soluble in water) and cannot be used directly by plants. Elemental sulfur (ES) is sometimes mixed with bentonite to amend depleted soils for crops with high requirement in organo-sulfur.
Congress passed the Authorization for the use of Military Force Against Terrorists, which grants the President the authority to use all "necessary and appropriate force" against those whom he determined "planned, authorized, committed or aided" the September 11 attacks or who harbored said persons or groups. It is still in effect. On October 7, 2001, the war in Afghanistan began when U.S. and British forces initiated aerial bombing campaigns targeting Taliban and al-Qaeda camps, then later invaded Afghanistan with ground troops of the Special Forces. This eventually led to the overthrow of the Taliban's rule of Afghanistan with the Fall of Kandahar on December 7, by U.S.-led coalition forces.
== Development == C-4 is a member of the Composition C family of chemical explosives. Variants have different proportions and plasticisers and include compositions C-2, C-3, and C-4. The original RDX-based material was developed by the British during World War II and redeveloped as Composition C when introduced to the U.S. military. It was replaced by Composition C-2 around 1943 and later redeveloped around 1944 as Composition C-3. The toxicity of C-3 was reduced, the concentration of RDX was increased, giving it improved safety during usage and storage. Research on a replacement for C-3 was begun prior to 1950, but the new material, C-4, did not begin pilot production until 1956. C-4 was submitted for patent as "Solid Propellant and a Process for its Preparation" March 31, 1958, by the Phillips Petroleum Company.
Sources: en.wikipedia.org
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.
It has not been approved by major regulatory agencies for any therapeutic indication. Material sold under this name is typically distributed for laboratory research only. Clinical use is not supported by large controlled trials.
Early human studies of the albumin-binding form reported circulation half-lives on the order of several days. The value depends on assay method and study design. Estimates for the form without the binding moiety are considerably shorter.
No. It is a laboratory-made analog of growth hormone-releasing hormone. The natural hormone is a 44-residue peptide, while the analog is built on a shorter 29-residue fragment.